Drug intelligence / Profile preview

SAR442501

Development stage: Phase 1
Lead developer: Sanofi
Modality: IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

SAR442501 is a humanized monoclonal antibody derivative developed for the treatment of achondroplasia, the most common form of dwarfism. It specifically targets and binds to fibroblast growth factor receptor 3 (FGFR3), inhibiting its overactive signaling caused by genetic mutations in achondroplasia. By limiting FGFR3 activity, SAR442501 aims to improve and restore normal skeletal growth in affected children. The drug is administered via subcutaneous injection and is currently under investigation in Phase 2 clinical trials for pediatric patients with achondroplasia[1][2][3][6][7].

Other names: FGFR3 antibody - SanofiFGFR-3 antibody - SanofiFGFR 3 antibody - Sanofi

Targets

FGFR3 (Fibroblast growth factor receptor 3)

Beyond the preview

Go deeper on SAR442501.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SAR442501.

Explore the full profile